Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
CC transcript
Inv. presentation
Quarterly results
|
|
Ensysce Biosciences, Inc. (LACQ)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/31/2022 |
8-K
| Quarterly results |
| 11/16/2021 |
8-K
| Quarterly results|
Docs:
|
"Ensysce Biosciences, Inc. Unaudited Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Federal grants $ 1,200,816 $ 827,639 $ 1,895,907 $ 3,514,720 Operating expenses: Research and development 1,714,635 892,991 2,502,232 3,136,207 General and administrative 16,372,976 339,422 17,257,361 898,470 Total operating expenses 18,087,611 1,232,413 19,759,593 4,034,677 Loss from operations Total other income , net 1,955,280 340,742 Net income $ $ 1,550,506 $ $ Ensysce Biosciences, Inc. Unaudited Condensed Consolidated Balance Sheets" |
|
| 08/16/2021 |
8-K
| Quarterly results|
Docs:
|
"Ensysce Biosciences, Inc. Unaudited Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Federal grants $ 444,516 $ 1,824,681 $ 695,091 $ 2,687,081 Operating expenses: Research and development 463,219 1,404,246 787,595 2,243,217 General and administrative 393,914 281,354 884,386 559,047 Total operating expenses 857,133 1,685,600 1,671,981 2,802,264 Income from operations 139,081 Total other income , net Net loss $ $ $ $ Ensysce Biosciences, Inc. Unaudited Condensed Consolidated Balance Sheets" |
|
|
|